A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer

Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics. CA Cancer J Clin 55(1):10–30

Ries L, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, Mariotto A, Feuer EJ, Edwards BK (2006) SEER cancer statistics review, 1975–2003. Bethesda. National Cancer Institute, MD

Takhar AS, Palaniappan P, Dhingsa R, Lobo DN (2004) Recent developments in diagnosis of pancreatic cancer. BMJ 329(7467):668–673

Donghui L, Keping X, Robert W, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363(9414):1049–1057

Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushai S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD (2000) Resected adenocarcinoma of the pancreas -616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4(6):567–579

Abrams RA (2003) Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985? Int J Radiat Oncol Biol Phys 56(Suppl 4):3–9

Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Berger H, Fernandez-Cruz L, Dervenis C, Lacaine F et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12):1200–1210

Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54(11):2856–2860

Pierre G, Jenny V, Laurence Z, Théry C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621–667

Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10(5):475–480

Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME, Weber J (2001) Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24(1):66–78

Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, Bernstein S, Venzon D, Gause B, Marincola F, Khleif SN (2008) Pilot study of mutant Ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 57(9):1413–1420

Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mulé JJ (2002) A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8(4):1021–1032

Pecher G, Häring A, Kaiser L, Thiel E (2002) Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51(11–12):669–673

Jacques B, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5(4):296–306

Asavaroengchai W, Kotera Y, Mule JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 99(2):931–936

Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4(1):45–60

Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V et al (2006) Mannan-MUC1 pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 12(3):869–877

Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK (1999) Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59(1):56–58

Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth RJ (2001) Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 61(2):641–646

Fong L, Brockstedt D, Benike C, Wu L, Engleman EG (2001) Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166(6):4254–4259

Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3):328–332

Lawrence F, Edgar GE (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245–273

Barth RJ, Mule JJ, Spiess PJ, Rosenberg SA (1991) Interferon γ and tumor necrosis factor have a role in tumor regression mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173(3):647–658

Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, Eberlein TJ (1998) Successful adoptive cellular immuno-therapy is dependent on induction of a host immune response triggered by cytokine (IFN-γ and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. J Immunol 160(1):334–344

Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ (1994) Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76(6):977–987